Literature DB >> 22121001

Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up?

S M Hosseini-Moghaddam1, E Iran-Pour, C Rotstein, S Husain, L Lilly, E Renner, T Mazzulli.   

Abstract

Chronic hepatitis C virus (HCV) infection which is often a silent disease has resulted in a global epidemic. The diagnosis of hepatitis C virus often requires confirmation with molecular techniques such as the polymerase chain reaction for detection of HCV RNA. Following laboratory confirmation of the diagnosis, molecular techniques are routinely used to monitor HCV RNA levels, particularly in those undergoing treatment. Unfortunately, molecular tests are relatively expensive and their cost may be prohibitive in the developing world. Several studies have investigated the applicability of the hepatitis C core Ag (HCVcAg), as a substitute for measuring HCV RNA levels. In this review, we provide an overview of the major findings of these studies focused on the utility of measuring HCVcAg antigen levels in the clinical setting. Overall, measuring HCVcAg levels is associated with several advantages and disadvantages. It may be useful in different clinical settings for monitoring HCV patients after obtaining an initial baseline HCV RNA result.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22121001     DOI: 10.1002/rmv.717

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  13 in total

Review 1.  New virologic tools for management of chronic hepatitis B and C.

Authors:  Stéphane Chevaliez; Christophe Rodriguez; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 2.  Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Authors:  Mahrukh Akbar Shaheen; Muhammad Idrees
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Rapid diagnostic HCV antibody assays.

Authors:  Bryce D Smith; Amy Jewett; Jan Drobeniuc; Saleem Kamili
Journal:  Antivir Ther       Date:  2012-12-07

Review 4.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations.

Authors:  Hsin-Yun Sun; Wang-Da Liu; Chih-Wen Wang; Yu-Ju Wei; Kuan-Yin Lin; Yu-Shan Huang; Li-Hsin Su; Yi-Ting Chen; Wen-Chun Liu; Yi-Chin Su; Yea-Wen Chen; Yu-Chung Chuang; Po-Liang Lu; Chien-Ching Hung; Ming-Lung Yu
Journal:  Microbiol Spectr       Date:  2022-05-17

6.  New markers for diagnosis and management of chronic hepatitis C virus infection.

Authors:  Stephane Chevaliez
Journal:  Ann Gastroenterol       Date:  2013

7.  HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b.

Authors:  Zhijuan Fan; Junfeng Liu; Fengmei Wang; Jingmin Liu; Xian Ding; Shuye Liu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

8.  The correlation of HCV RNA and HCV core antigen in different genotypes of HCV.

Authors:  Yu Xiang; Xiao-Fei Lai; Pu Chen; Yang Yang
Journal:  J Clin Lab Anal       Date:  2018-08-01       Impact factor: 2.352

9.  Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.

Authors:  Nikolien van de Ven; Joe Fortunak; Bryony Simmons; Nathan Ford; Graham S Cooke; Saye Khoo; Andrew Hill
Journal:  Hepatology       Date:  2015-02-09       Impact factor: 17.425

10.  Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.

Authors:  Bo Feng; Rui-Feng Yang; Qing Xie; Jia Shang; Fan-Yun Kong; Hai-Ying Zhang; Hui-Ying Rao; Qian Jin; Xu Cong; Yun-Ye Liu; Yi Kang; Lai Wei
Journal:  BMC Gastroenterol       Date:  2014-03-13       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.